Pharnext S.C.A.
7
0
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
43%
3 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
The Impact of Charcot-Marie-Tooth Disease in the Real World
Role: collaborator
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients
Role: lead
Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A
Role: lead
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
Role: lead
Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A
Role: lead
Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)
Role: lead
24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion
Role: lead
All 7 trials loaded